Premium
Anti‐HBs responses after combined injection of recombinant yeast and plasma‐derived hepatitis B vaccines
Author(s) -
YOSHIDA KEN,
FUJIYAMA SHIGETOSHI,
SATO TATSUO,
MIZUNO KYOSUKE
Publication year - 1988
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/j.1440-1746.1988.tb01397.x
Subject(s) - recombinant dna , seroconversion , medicine , virology , antigenicity , yeast , hepatitis b vaccine , titer , antibody , vaccination , group a , group b , immunology , hepatitis b virus , biology , virus , hbsag , biochemistry , genetics , gene
Anti‐HBs responses to a combined injection of recombinant yeast and plasma‐derived hepatitis B vaccines were evaluated in 119 healthy members of medical staff. They were divided into three age‐ and sex‐matched groups. Group I (YHB‐YHB‐YHB) were given recombinant yeast vaccine at 0, 1 and 6 months, group II (PHB‐YHB‐YHB) were given plasma‐derived vaccine at 0 month, and then recombinant yeast vaccine at 1 and 6 months, and group III (YHB‐YHB‐PHB) were given recombinant yeast vaccine at 0 and 1 month and then plasma‐derived vaccine at 6 months. The seroconversion rate in each group at 7 months were similar (group I: 91.2%, group II: 88.5%, and group III: 94.1%). Acquired antibody titre (S/N ratio) was higher, however, in group II than in group I (group I: 37.6 ± 29.1 versus group II: 57.4 ± 44.9). The present study indicated that in this combined injection method, cross antigenicity was observed between plasma‐derived vaccine and recombinant yeast vaccine and that high antibody titres could be obtained by a combined injection of a recombinant yeast vaccine and a plasma‐derived vaccine when compared with the recombinant vaccine alone. Accordingly, this combined vaccination method is recommended because of its easy availability.